Some have gone off without a hitch, while others fell into serious scrutiny as mouthwatering financial figures were revealed and major technologies were acquired.
Here are the 10 biggest mergers and acquisitions in medtech in 2021:
Next>Thermo Fisher Scientific (NYSE:TMO) today posted third-quarter results that beat the overall consensus on Wall Street.
The Waltham, Massachusetts-based laboratory supply company reported profits of $1.9 billion, or $4.79 per share, on sales of $9.3 billion for the three months ended October 2, for a bottom-line loss of -1.6% on sales growth of 9.49% compared with Q3 2020.
Get the full story on our sister site, Medical Design & Outsourcing.
Thermo Fisher Scientific (NYSE:TMO) today posted second-quarter results that beat the overall consensus on Wall Street.
The Waltham, Mass.-based company reported profits of $1.8 billion, or $4.61 per share, on sales of $9.3 billion for the three months ended July 1, 2021, for a bottom-line gain of 58.1% on sales growth of 34.1% compared with Q2 2020.
Get the full story on our sister site, Medical Design & Outsourcing.
The medtech industry hit a slight lull in the early stages of 2021 and, after signs of a rebound, it has soared beyond levels ever before seen.
MassDevice‘s MedTech 100 Index had been building up steam in the month of April, rising from 102.16 points at the beginning of March all the way to 109.39 to end the week before last (April 9). Having only set its previous all-time best of 110.96 on Feb. 15, the industry’s topsy-turvy run gave no indication of which direction it was heading next.
However, after the rise over the past couple of weeks, the industry rode that wave to a new all-time high of 112.25 to end last week on April 16. That represents a 2.6% rise from the previous week’s tally.
Improvements continue to shine a light on the strong position the industry has settled into a year on from the height of the COVID-19 pandemic’s impact on medtech, as the industry has produced an 21.6% rise from the pre-pandemic high of 92.32 (set on Feb. 1…
Thermo Fisher Scientific (NYSE:TMO) announced today that it agreed to acquire PPD (NSDQ:PPD) for $17.4 billion.
The boards of directors for both companies approved the definitive agreement, which will see Thermo Fisher buy PPD for $47.50 per share, totaling $17.4 billion, plus the assumption of approximately $3.5 billion of net debt, according to a news release. That represents a premium of approximately 24% to the unaffected closing price of PPD’s common stock on Tuesday, April 13, 2021.
Get the full story at our sister site, Drug Discovery & Development.
Hologic CEO Steve MacMillan says in early March 2020 he didn’t appreciate how COVID-19 would change the world forever. But the diagnostics company quickly rose to the challenge, becoming one of the surer suppliers of diagnostic tests needed to chart the Coronavirus’ severity.
In this DeviceTalks Weekly Podcast, MacMillan shares how Hologic pivoted to meet the calls for help from political leaders in the US and around the world.
He also shares what’s next for the company which has shed its aesthetics business in favor of a tighter new course, a course that includes the creation of an innovative information index that will yield new data on women’s health.
While Hologic rose to the challenge during the pandemic, GuardianLane is ready to help children who are coping with grief, including the loss of loved ones to COVID-19 and other diseases.
CEO Kristina Jones shares the story that won the first pitch contest held by Medtech Color, an organization fo…
Thermo Fisher Scientific and Mayo Clinic today announced a new collaboration that will take place near the respected health provider’s main Rochester, Minn. campus.
The partnership will focus on accelerating clinical validation and commercialization of certain next-generation sequencing (NGS), mass spectrometry and immunology diagnostic tools. Work will occur at the Advanced Diagnostics Laboratory at the 90,000-square-foot One Discovery Square that opened off Mayo Clinic’s Rochester campus in 2019.
“By pairing cutting-edge, innovative technologies with world-class clinical and diagnostic testing knowledge, this collaboration will ensure that the promising innovations are both clinically relevant and accessible globally,” said Dr. William Morice II, chair of Mayo Clinic’s Department of Laboratory Medicine and Pathology and president of Mayo Clinic Laboratories.
The Mayo Clinic and…
The AerosolSense Sampler collects representative aerosol samples of ambient air and traps in-air pathogens on a collection substrate. The sample can be readily analyzed through subsequent laboratory testing using polymerase chain reaction (PCR) methodology. The extra information can help leaders at hospitals and other indoor facilities better take actions to protect people — and boost confidence that particular spaces are safe.
Get the full story on our sister site Medical Design & Outsourcing.
On the back of several weeks of new records and strong performances, the medtech industry has finally hit a snag in its recent ascent.
MassDevice‘s MedTech 100 index ended the week (Feb. 26) at 106.65 points, marking a 1.9% dip from the 108.72-point mark set one week before (Feb. 19). This highlights a similar drop from the week prior, when the index slid -1.7% from 110.63 points on Feb. 12.
The slide for the index was inevitable, given the heights to which it had been rising, but it is stark after exactly two weeks ago, on Monday, Feb. 15, the index hit its highest mark ever, though, rising to 110.96 points. That mark set an all-time best for the index, which had previously been rising for practically all of 2021. The index had never reached even the 100-point mark before November 2020.
Still, the industry is in much better condition than it was around this time last year. Medtech’s latest mark means the index has risen 15.5% from the pre-COVID-19 pande…
Thermo Fisher Scientific (NYSE:TMO) announced today that completed its previously announced acquisition of Mesa Biotech.
Last month, Waltham, Mass.-based Thermo Fisher announced its agreement to buy the point-of-care molecular diagnostic developer for approximately $450 million in cash. Mesa Biotech will become part of Thermo Fisher’s life sciences solution segment and is expected to bring in revenue of approximately $200 million in 2021, according to a news release.
The San Diego-based company has approximately 500 employees and revenues in 2020 of approximately $45 million.
Under the terms of the agreement, Thermo Fisher will pay up to an additional $100 million in cash upon the completion of certain milestones as well.
Mesa Biotech develops the Accula system for point-of-care PCR-based testing for infectious disease diagnoses. The affordable, easy-to-use platform enables rapid, accurate testing at physician offices, pharmacies and other s…
Inspire Medical CEO Tim Herbert never set out to be a CEO. Yet, he spun of a promising sleep apnea technology out of Medtronic and assembled a team that not only went public, but helps hard-to-treat apnea patients live healthier lives through better sleep.
Oh, and the electrical engineer turned startup-CEO took the medtech public in 2018. Listen to this episode to hear how Inspire management worked with the FDA, payers and public investor to build a burgeoning neuromed giant.
Co-host Tom Salemi also talks to Rob Bodor, the incoming CEO at Protolabs. Bodor succeeds the highly successful Vicki Holt who built the manufacturing company into an acquisitive powerhouse. Hodor shares what’s next for the company.
Co-cost Chris Newmarker, executive editor of life sciences at MassDevice, unveils this week’s Newmarker’s Newsmakers featuring news from Thermo Fisher Scientific, Mainstay Medical, Theranos, Butterfly Networks and Zimmer Biomet’s …
Thermo Fisher Scientific (NYSE:TMO) announced today that it received FDA emergency use authorization (EUA) for a COVID-19/flu combo test.
Carlsbad, Calif.-based Thermo Fisher’s Applied Biosystems TaqPath COVID-19, Flu A, Flu B combo kit is a real-time PCR test for detecting and differentiating RNA from SARS-CoV-2, influenza A and influenza B viruses in nasopharyngeal and nasal swabs, according to a news release.
The company’s kit includes Applied Biosystems pathogen-interpretive software for converting genetic analysis data into a readable report automatically to reduce the risk of errors with interpretation, Thermo Fisher said.
Testing with the TaqPath COVID-19, Flu A, Flu B combo kit is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. 263a, to perform high-complexity tests, or by similarly qualified non-U.S. laboratories.
“Understanding that the flu season would ov…